Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis
- PMID: 15746043
- DOI: 10.1158/1078-0432.CCR-04-1870
Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis
Abstract
Purpose: Vascular endothelial growth factor (VEGF) is considered as a prime mediator of angiogenesis. Various studies examining the relationship between VEGF protein overexpression with the clinical outcome in patients with head and neck squamous cell carcinoma have yielded inconclusive results.
Experimental design: We conducted a meta-analysis of 12 studies (n = 1.002 patients) that evaluated the correlation between VEGF (detected by immunohistochemistry) and 2-year overall survival. The relation between VEGF and lymph node involvement (11 studies, n = 722) was also examined. Data were synthesized with random effect and fixed effect risk ratios.
Results: The estimated risk of death in 2 years was 1.88-fold higher in the VEGF-positive patients [95% confidence interval, 1.43-2.45; P < 0.001 random effect calculations]. Between-study heterogeneity was nonsignificant (P = 0.15) but larger studies tended to provide more conservative estimates (P = 0.097). VEGF overexpression was not significantly associated with the presence of lymph node metastasis (risk ratio, 1.20; 95% confidence interval, 0.97-1.49; P = 0.087) and there was significant between-study heterogeneity (P = 0.08).
Conclusions: Although some modest bias cannot be excluded, VEGF positivity seems to be associated with worse overall survival in patients with head and neck squamous cell carcinoma.
Similar articles
-
Vascular endothelial growth factor a and proliferation marker in prediction of lymph node metastasis in oral and pharyngeal squamous cell carcinoma.Arch Otolaryngol Head Neck Surg. 2008 Dec;134(12):1305-11. doi: 10.1001/archotol.134.12.1305. Arch Otolaryngol Head Neck Surg. 2008. PMID: 19075127
-
Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma.Oncol Rep. 2003 Sep-Oct;10(5):1073-9. Oncol Rep. 2003. PMID: 12883661
-
Strong immunohistochemical expression of vascular endothelial growth factor predicts overall survival in head and neck squamous cell carcinoma.Ann Surg Oncol. 2007 Dec;14(12):3558-65. doi: 10.1245/s10434-007-9632-0. Epub 2007 Oct 11. Ann Surg Oncol. 2007. PMID: 17929099
-
Meta-analysis of the prognostic significance of perinodal spread in head and neck squamous cell carcinomas (HNSCC) patients.Eur J Cancer. 2006 Aug;42(12):1863-8. doi: 10.1016/j.ejca.2006.01.062. Epub 2006 Jul 10. Eur J Cancer. 2006. PMID: 16831543 Review.
-
Prognostic value of vascular endothelial growth factor in patients with head and neck cancer: A meta-analysis.Head Neck. 2013 Oct;35(10):1507-14. doi: 10.1002/hed.23156. Epub 2012 Sep 18. Head Neck. 2013. PMID: 22987573 Review.
Cited by
-
MRI Radiomics for Predicting Survival in Patients with Locally Advanced Hypopharyngeal Cancer Treated with Concurrent Chemoradiotherapy.Cancers (Basel). 2022 Dec 12;14(24):6119. doi: 10.3390/cancers14246119. Cancers (Basel). 2022. PMID: 36551604 Free PMC article.
-
Expression of EGFR, VEGF, and NOTCH1 suggest differences in tumor angiogenesis in HPV-positive and HPV-negative head and neck squamous cell carcinoma.Head Neck Pathol. 2013 Dec;7(4):344-55. doi: 10.1007/s12105-013-0447-y. Epub 2013 May 4. Head Neck Pathol. 2013. PMID: 23645351 Free PMC article.
-
Molecular characterization of head and neck cancer: how close to personalized targeted therapy?Mol Diagn Ther. 2012 Aug 1;16(4):209-22. doi: 10.2165/11635330-000000000-00000. Mol Diagn Ther. 2012. PMID: 22873739 Free PMC article.
-
Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma.Head Neck. 2016 Apr;38 Suppl 1(Suppl 1):E566-70. doi: 10.1002/hed.24041. Epub 2015 Jul 6. Head Neck. 2016. PMID: 25784616 Free PMC article. Clinical Trial.
-
Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines.Br J Cancer. 2010 Jan 5;102(1):173-80. doi: 10.1038/sj.bjc.6605462. Epub 2009 Dec 8. Br J Cancer. 2010. PMID: 19997101 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical